Can I Get a Michigan Medical Marijuana Card for HIV / AIDS?
HIV/AIDS-related wasting, nausea, neuropathic pain.
Yes — hiv / aids qualifies under the Michigan Medical Marihuana Program
HIV/AIDS is an explicit qualifying condition under the Michigan Medical Marihuana Program (MMMA). Medical cannabis has one of the longest histories of recognized supportive use in any condition — synthetic THC (dronabinol/Marinol) has been FDA-approved for AIDS-related anorexia since 1992, predating most other modern cannabinoid approvals by decades. Patients living with HIV in Michigan use medical cannabis primarily for the constellation of symptoms that can accompany either the disease itself or long-term antiretroviral therapy: appetite loss, nausea, painful peripheral neuropathy, and sleep difficulty.
Common symptoms
- Cachexia / wasting and weight loss
- Nausea (from disease or antiretroviral therapy)
- HIV-associated neuropathic pain
- Appetite loss
- Sleep disturbance
- Anxiety related to diagnosis or treatment
How medical cannabis may help
The FDA approved synthetic THC (dronabinol, brand name Marinol) for chemotherapy-induced nausea in 1985 and for AIDS-related anorexia/cachexia in 1992. THC stimulates appetite via CB1 receptors in the hypothalamus, reduces nausea via brainstem antiemetic pathways, and addresses HIV-associated peripheral neuropathy through cannabinoid receptors in peripheral nerves. Many HIV patients find cannabis particularly useful because it addresses several common HIV-related issues with one therapy rather than stacking appetite stimulants, antiemetics, and neuropathic-pain medications.
Evidence base
The FDA approval of dronabinol for AIDS anorexia is supported by randomized controlled trials demonstrating weight gain and improved appetite. Subsequent research, including studies on HIV-associated neuropathic pain published in Neurology and other peer-reviewed journals, has documented meaningful pain reduction with cannabis. Decades of clinical use in HIV care — both before and after the era of effective combination antiretroviral therapy — support cannabinoids as a recognized component of HIV symptom management.
Michigan certification requirements
Documentation of HIV/AIDS diagnosis from your treating physician (HIV specialist, infectious disease physician, or primary care provider managing your HIV care). Recent labs (viral load, CD4 count) and a list of your current antiretroviral regimen are helpful but not strictly required. Coordination with your HIV provider about adding cannabis to your symptom-management plan is strongly encouraged for safety and continuity of care.
Frequently Asked Questions
- Will cannabis interact with my antiretroviral medications?
- Some antiretrovirals — particularly protease inhibitors and certain integrase inhibitors — are metabolized by cytochrome P450 enzymes (especially CYP3A4) that also metabolize cannabinoids. THC and CBD can inhibit these enzymes, which could in theory affect antiretroviral drug levels. Most modern HIV regimens have minimal clinically significant interactions, but Dr. Vance will review your specific regimen during the consultation.
- Will cannabis affect my viral suppression?
- Cannabis itself does not interfere with antiretroviral efficacy when ART is taken consistently. The most important factor for viral suppression is medication adherence — discuss any concerns with your HIV provider.
- Does Michigan accept HIV diagnosis from any provider?
- Yes. A diagnosis from any qualified medical provider is sufficient documentation. The Michigan certification itself must be issued by a Michigan-licensed physician (such as Dr. Vance).
- Will my HIV care team know I have a Michigan medical marijuana card?
- Michigan MMMP data is confidential under MCL 333.26426(h). Your HIV or infectious disease provider will only know if you disclose it. However, coordination is important — cannabis can interact with some antiretroviral medications (HAART) via drug-metabolizing enzymes. Sharing your medical cannabis use helps your HIV team adjust monitoring.
- How does the phone consultation work for an HIV/AIDS patient?
- The visit is 10–15 minutes. Dr. Vance discusses your diagnosis, current antiretroviral regimen, and what symptoms you're managing with medical cannabis (wasting, appetite loss, nausea, neuropathic pain). Recent bloodwork isn't required upfront, though your HIV team's records can speed the evaluation.
- Does medical cannabis interact with antiretroviral therapy (HAART)?
- Cannabis compounds affect the same drug-metabolizing enzymes (CYP450) that process many HAART medications. Coordination with your HIV care team is essential before adjusting either your HAART regimen or your cannabis use. Dr. Vance provides the Michigan certification; HAART management stays with your infectious disease team.